Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (trading symbol: OCX) on August 9, 2019. The filing discloses the appointment of a new senior executive officer. The company is incorporated in California and its common stock is registered on the NYSE American.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
The primary material change reported is the appointment of Tony Kalajian as Senior Vice President and Chief Accounting Officer, effective August 9, 2019. Mr. Kalajian previously served as the Vice President and Chief Accounting Officer for OncoCyte's former parent company, Lineage Cell Therapeutics, Inc. (formerly BioTime Inc.), where he managed financial reporting for OncoCyte and other spun-off entities.
Guidance, Outlook, and Compensation Details
The filing outlines the proposed compensation package for Mr. Kalajian, subject to approval by the Compensation Committee:
- Base Salary: $325,000 annually.
- Annual Bonus: Target of 40% of base salary, based on company and individual objectives.
- Equity Grant: Options to purchase 275,000 shares of common stock under the 2018 Equity Incentive Plan.
- Vesting Schedule: 87,500 shares vest after one year of continuous service; the remaining 187,500 shares vest in 36 equal monthly installments.
- Termination Provisions:
- Without Cause/Good Reason: Entitlement to six months' base salary and acceleration of 35% of unvested options.
- Change in Control: If termination occurs within 12 months of a change in control, 50% of unvested options accelerate.
The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to risk factors detailed in recent Form 10-K and 10-Q filings.
Investor Verification Checklist
- Verify the final approval of Mr. Kalajian's employment agreement and compensation terms by the Compensation Committee.
- Review the specific exercise price of the 275,000 stock options, which is determined by the 2018 Equity Incentive Plan but not explicitly stated in this filing.
- Confirm the impact of this leadership change on the company's financial reporting processes, given Mr. Kalajian's prior role managing OncoCyte's accounting under a shared services agreement.
- Check recent Form 10-K and 10-Q filings for updated risk factors and financial performance data not included in this 8-K.